Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Alectinib in ALK-rearranged NSCLC after crizotinib
NCT03155009Phase 2Completed
- Sponsor
- Roche
- Start
- Jul 2017
- Primary completion
- Sep 2019
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 2 trial of alectinib in non-small cell lung cancer (NSCLC), sponsored by Roche. Started Jul 2017; status: completed.
02
Drugs
alectinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT03155009.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03155009.